Monitoring of Risedronate by biochemical bone markers in clinical practice.

Simple item page
dc.contributor.authorBunyaratavej, Narongen_US
dc.date.accessioned2009-05-27T20:33:19Z
dc.date.available2009-05-27T20:33:19Z
dc.date.issued2005-10-16en_US
dc.descriptionChotmaihet Thangphaet.en_US
dc.description.abstractThe study of trend of Risedronate 10 mg/day in menopausal women with a high level of resorptive bone marker (Betacrosslaps, CTx) by the following bone markers:Bone alkaline phosphatase (formation marker) total alkaline phosphatase (TAlP), NMID osteocalcin, undercarboxylated osteocalcin (UcOC) and procollagen type 1 carboxyl propeptides (PICP). Risedronate does not suppress bone resorption deeply that enhances the bone recovers quickly after withdrawal. The level of undercarboxylated osteocalcin was increased after one year of treatment; it may be a sign of vitamin K2 deficiency. The bone alkaline phosphatase was decreased at the end of 12 months and Procollagen type 1 carboxyl propeptides (PICP) of twelfth month changed significantly compared to the sixth months of treatment (p=0.001) The once week 70 mg/week group also changed of CTx the same as daily dose group.en_US
dc.description.affiliationDepartment of Orthopaedic Surgery, Faculty of Medicine, Mahidol University, Bangkok 10700, Thailand. todrnarong@yahoo.comen_US
dc.identifier.citationBunyaratavej N. Monitoring of Risedronate by biochemical bone markers in clinical practice. Journal of the Medical Association of Thailand. 2005 Oct; 88(suppl 5): S34-6en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/43210
dc.language.isoengen_US
dc.source.urihttps://www.mat.or.th/journal/all.phpen_US
dc.subject.meshAlkaline Phosphatase --drug effectsen_US
dc.subject.meshBiological Markers --analysisen_US
dc.subject.meshBone Density --drug effectsen_US
dc.subject.meshBone Density Conservation Agents --administration & dosageen_US
dc.subject.meshBone Resorption --drug therapyen_US
dc.subject.meshBone and Bones --drug effectsen_US
dc.subject.meshDrug Monitoringen_US
dc.subject.meshEtidronic Acid --administration & dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOsteocalcin --drug effectsen_US
dc.subject.meshOsteoporosis, Postmenopausal --drug therapyen_US
dc.subject.meshPeptide Fragments --drug effectsen_US
dc.subject.meshProcollagen --drug effectsen_US
dc.subject.meshTime Factorsen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshVitamin K Deficiencyen_US
dc.titleMonitoring of Risedronate by biochemical bone markers in clinical practice.en_US
dc.typeClinical Trialen_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of the Medical Association of Thailand